MENU

Primary tabs

Fox Chase Cancer Center News

Primary tabs

February 17, 2022

Finding by Fox Chase Researchers That YAP1 Molecule is Essential to Development of Gastruloids Using Embryonic Stem Cells May Have Implications for Cancer

PHILADELPHIA (February 17, 2022)—Researchers at Fox Chase Cancer Center have discovered that the Hippo signaling effector YAP1 is a master regulator of Nodal signaling in human embryonic stem cells (hESCs) for a process essential to human development.

February 15, 2022

Dr. Efrat Dotan Appointed Vice Chair of Pancreas Task Force for the National Cancer Institute

PHILADELPHIA (February 15, 2022)—Efrat Dotan, MD, chief of the Division of Gastrointestinal Medical Oncology at Fox Chase Cancer Center, has been appointed the vice chair of the National Cancer Institute’s (NCI) Pancreas Task Force as part of the Gastrointestinal Steering Committee (GISC).

February 14, 2022

Fox Chase Researchers Find Nivolumab and Axitinib Combination Effective in Patients With Advanced Renal Cell Carcinoma

PHILADELPHIA (February 14, 2022)—Data from researchers at Fox Chase Cancer Center indicates that advanced kidney cancer patients treated with a combination of nivolumab and axitinib experienced similar therapeutic benefits to those patients treated with other drug combinations with similar safety profiles. The new research was presented at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, which is being held February 17-19.

February 11, 2022

Fox Chase Cancer Center Receives Prestigious Research Education Program Grant to Expand Undergraduate Research Opportunities

PHILADELPHIA (February 11, 2022)—Fox Chase Cancer Center has been awarded a Research Education Program grant that will allow the center to expand the reach of its University of Delaware-Fox Chase Cancer Center Summer Research Fellowship.

February 10, 2022

Fox Chase Cancer Center’s Johnathan Whetstine Receives a Maximizing Investigators’ Research Award

PHILADELPHIA (February 10, 2022)—Johnathan R. Whetstine, PhD, director of the Cancer Epigenetics Institute at Fox Chase Cancer Center, was recently honored with a Maximizing Investigators’ Research Award (MIRA) from the National Institute of General Medical Sciences (NIGMS). This five-year grant will fund fundamental research on DNA amplification and uncovering pathways that control it.

February 7, 2022

Study Finds COVID-19 Vaccines Using mRNA Technology Safe for People With Cancer

PHILADELPHIA (February 7, 2022)—According to a new study from researchers at Fox Chase Cancer Center, mRNA vaccine for COVID-19 is just as safe for people with cancer as it is for cancer-free individuals.

February 3, 2022

Fox Chase’s Linda Fleisher Receives Academy of Oncology Nurse & Patient Navigators Lifetime Achievement Award

PHILADELPHIA (February 3, 2022)—Linda Fleisher, PhD, MPH, associate research professor in the Cancer Prevention and Control research program at Fox Chase Cancer Center, was recently recognized with the Lillie D. Shockney Lifetime Achievement Award from the Academy of Oncology Nurse & Patient Navigators (AONN+).

February 1, 2022

Researchers Find Chronic Fatigue Following COVID-19 Infection Could Be Related to Endocrine Function

PHILADELPHIA (February 1, 2022)—Patients recovering from COVID-19 who continue to have certain debilitating symptoms such as chronic fatigue may need long-term support, including evaluation of the endocrine system, according to a recent review.

Pages

Connect with Fox Chase